🔴 Sunshine Biopharma is trading 6.1% down with no clear catalyst identified

On November 2, 2026, Sunshine Biopharma is trading 6.1% lower at $2.75, with no clear catalyst identified.

• The latest prominent company news was an October 22 announcement of a 1-for-20 reverse stock split, effective October 26, to regain Nasdaq’s minimum bid-price compliance.
• XBI is down 2.39%, while major indexes are higher. The available evidence does not establish a sector or market catalyst, and trading volume or activity level is unconfirmed.